ROIV
Roivant Sciences Ltd
35.90$
-2.8%
vs. previous close
Closing price · As of: Nov 2, 2026
Ownership
Ownership Structure
Who owns Roivant Sciences Ltd (ROIV)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 80.6% of the shares are freely tradable; institutional investors hold 75.9%.
Institutional ownership
?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
75.9%
Insiders
?Share of the stock held by the executives, founders and major shareholders of the company itself.
23.4%
Float
?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
80.6%
Short % of float
?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
7.4%
Shares Outstanding
?Total number of shares issued. Price times share count gives market cap.
722Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 11.22 | 81,020,390 | +3.9 | 06/30/2026 |
| BlackRock Inc | 6.68 | 48,236,091 | +9.0 | 06/30/2026 |
| Morgan Stanley - Brokerage Accounts | 5.90 | 42,592,905 | -17.8 | 06/30/2026 |
| Qvt Financial LP | 3.28 | 23,723,074 | -5.7 | 06/30/2026 |
| Vanguard Capital Management, LLC | 3.06 | 22,123,198 | +7.0 | 06/30/2026 |
| Vanguard Portfolio Management, LLC | 3.00 | 21,641,339 | +9.1 | 06/30/2026 |
| The Goldman Sachs Group Inc | 2.57 | 18,556,458 | +67.0 | 06/30/2026 |
| State Street Corp | 2.46 | 17,795,975 | +9.9 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 3.19 | 23,009,528 | +0.2 | 08/31/2026 |
| iShares Core S&P Mid-Cap ETF | 2.67 | 19,297,013 | +0.0 | 09/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Roivant Sciences Ltd. | Director | 29,880,079 | 1,072,694,836 $ | Oct 1, 2026 | direct |
| Sukhatme Mayukh | President & CIO | 18,563,884 | 666,443,436 $ | Oct 16, 2026 | direct |
| Gline Matthew | CEO | 16,549,136 | 594,113,982 $ | Oct 16, 2026 | direct |
| Torti Frank | President and Vant Chair | 13,495,893 | 484,502,559 $ | Sep 30, 2026 | direct |
| Gold Daniel Allen | Director | 8,965,815 | 321,872,759 $ | Sep 16, 2026 | direct |
| Manchester Keith S | Director | 1,753,457 | 62,949,106 $ | Sep 16, 2026 | direct |
| Venker Eric | President & Immunovant CEO | 1,199,154 | 43,049,629 $ | Oct 28, 2026 | direct |
| Pulik Richard | CFO | 269,681 | 9,681,548 $ | Sep 20, 2026 | direct |
| Oren Ilan | Director | 124,490 | 4,469,191 $ | Oct 23, 2026 | direct |
| Momtazee James C | Director | 112,265 | 4,030,314 $ | Oct 23, 2026 | direct |
| Humes Jennifer | Chief Accounting Officer | 106,419 | 3,820,442 $ | Sep 20, 2026 | direct |
| Fitzgerald Meghan | Director | 41,162 | 1,477,716 $ | Sep 16, 2026 | direct |
| Epperly Melissa B, | Director | 15,351 | 551,101 $ | Oct 23, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 28, 2026 | Venker Eric | President & Immunovant CEO | Sell | 200,000 | 36.59 | 7,318,000 |
| Oct 23, 2026 | Epperly Melissa B, | Director | Other | 116 | 36.49 | 4,233 |
| Oct 23, 2026 | Epperly Melissa B, | Director | Other | 513 | 0.00 | – |
| Oct 23, 2026 | Oren Ilan | Director | Other | 810 | 0.00 | – |
| Oct 23, 2026 | Momtazee James C | Director | Other | 77 | 36.49 | 2,810 |
| Oct 23, 2026 | Momtazee James C | Director | Other | 383 | 0.00 | – |
| Oct 20, 2026 | Venker Eric | President & Immunovant CEO | Sell | 14,144 | 35.42 | 500,980 |
| Oct 20, 2026 | Venker Eric | President & Immunovant CEO | Sell | 185,856 | 35.09 | 6,521,687 |
| Oct 16, 2026 | Sukhatme Mayukh | President & CIO | Other | 19,976 | 33.53 | 669,795 |
| Oct 16, 2026 | Gline Matthew | CEO | Other | 34,638 | 33.53 | 1,161,412 |
| Oct 1, 2026 | Epperly Melissa B, | Director | Sell | 900 | 36.57 | 32,913 |
| Oct 1, 2026 | Epperly Melissa B, | Director | Sell | 16,850 | 36.08 | 607,948 |
| Oct 1, 2026 | Epperly Melissa B, | Director | Other | 17,750 | 4.46 | 79,165 |
| Oct 1, 2026 | Roivant Sciences Ltd. | Director | Other | 8,967,383 | 5.00 | 44,836,915 |
| Sep 30, 2026 | Sukhatme Mayukh | President & CIO | Other | 46,879 | 36.57 | 1,714,365 |
| Sep 30, 2026 | Venker Eric | President & Immunovant CEO | Sell | 200,000 | 36.62 | 7,324,000 |
| Sep 30, 2026 | Venker Eric | President & Immunovant CEO | Other | 200,000 | 3.85 | 770,000 |
| Sep 30, 2026 | Gline Matthew | CEO | Other | 76,171 | 36.57 | 2,785,573 |
| Sep 30, 2026 | Torti Frank | President and Vant Chair | Other | 40,309 | 36.57 | 1,474,100 |
| Sep 20, 2026 | Pulik Richard | CFO | Other | 2,129 | 39.77 | 84,670 |
| Sep 20, 2026 | Humes Jennifer | Chief Accounting Officer | Other | 3,880 | 39.77 | 154,308 |
| Sep 16, 2026 | Epperly Melissa B, | Director | Other | 5,054 | 0.00 | – |
| Sep 16, 2026 | Gold Daniel Allen | Director | Other | 5,054 | 0.00 | – |
| Sep 16, 2026 | Oren Ilan | Director | Other | 5,054 | 0.00 | – |
| Sep 16, 2026 | Fitzgerald Meghan | Director | Other | 5,054 | 0.00 | – |
| Sep 16, 2026 | Momtazee James C | Director | Other | 5,054 | 0.00 | – |
| Sep 16, 2026 | Manchester Keith S | Director | Other | 5,054 | 0.00 | – |
| Sep 15, 2026 | Epperly Melissa B, | Director | Sell | 600 | 40.38 | 24,228 |
| Sep 15, 2026 | Epperly Melissa B, | Director | Sell | 4,338 | 39.65 | 172,002 |
| Sep 15, 2026 | Fitzgerald Meghan | Director | Sell | 400 | 40.45 | 16,180 |
| Sep 15, 2026 | Fitzgerald Meghan | Director | Sell | 4,712 | 39.68 | 186,972 |
| Sep 10, 2026 | Epperly Melissa B, | Director | Other | 2,179 | 40.94 | 89,208 |
| Sep 10, 2026 | Oren Ilan | Director | Other | 2,378 | 40.94 | 97,355 |
| Sep 10, 2026 | Fitzgerald Meghan | Director | Other | 1,743 | 40.94 | 71,358 |
| Sep 10, 2026 | Momtazee James C | Director | Other | 2,905 | 40.94 | 118,931 |
| Sep 10, 2026 | Gold Daniel Allen | Director | Other | 5,133 | 40.94 | 210,145 |
| Sep 8, 2026 | Fitzgerald Meghan | Director | Sell | 20,000 | 39.90 | 798,000 |
| Sep 8, 2026 | Fitzgerald Meghan | Director | Other | 20,000 | 8.80 | 176,000 |
| Aug 28, 2026 | Venker Eric | President & Immunovant CEO | Sell | 33,818 | 36.44 | 1,232,328 |
| Aug 28, 2026 | Venker Eric | President & Immunovant CEO | Sell | 166,182 | 35.63 | 5,921,065 |
| Aug 28, 2026 | Venker Eric | President & Immunovant CEO | Other | 200,000 | 3.85 | 770,000 |
| Aug 21, 2026 | Sukhatme Mayukh | President & CIO | Sell | 144,756 | 36.48 | 5,280,699 |
| Aug 21, 2026 | Sukhatme Mayukh | President & CIO | Other | 144,756 | 3.85 | 557,311 |
| Aug 20, 2026 | Pulik Richard | CFO | Other | 5,749 | 36.84 | 211,793 |
| Aug 20, 2026 | Venker Eric | President & Immunovant CEO | Other | 13,909 | 36.84 | 512,408 |
| Aug 20, 2026 | Sukhatme Mayukh | President & CIO | Sell | 17,519 | 37.30 | 653,459 |
| Aug 20, 2026 | Sukhatme Mayukh | President & CIO | Other | 17,519 | 3.85 | 67,448 |
| Aug 19, 2026 | Sukhatme Mayukh | President & CIO | Sell | 172,899 | 37.17 | 6,426,656 |
| Aug 19, 2026 | Sukhatme Mayukh | President & CIO | Other | 172,899 | 3.85 | 665,661 |
| Aug 18, 2026 | Sukhatme Mayukh | President & CIO | Sell | 31,801 | 37.18 | 1,182,361 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: November 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.